To further elucidate how an early-phase activation of proinflammatory responses leads to a late-phase reduction of antitumor immunity in the colon of Dnase1l3-KO mice, we established a syngenic colon tumor model by s.c. injecting MC38 murine colon cancer cells into Dnase1l3 WT and Dnase1l3-KO mice. This evidence concerns the gene DNASE1L3 and malignant colon neoplasm.